Genetically determined oxidation polymorphism and drug hepatotoxicity. Study of 51 patients.

No abstract is available for this paper.

• Publication year

  1989

• Venue

  Journal of Hepatology

• Publication date

  1989-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/0168-8278(89)90003-2PMID 2715619
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 8 Acute and chronic drug-induced hepatitis

  1988cited by this paper
• Amitriptyline-induced prolonged cholestasis.

  1988cited by this paper
• Acute and chronic drug-induced hepatitis.

  1988cited by this paper
• Metoprolol-induced hepatitis: rechallenge and drug oxidation phenotyping.

  1988cited by this paper
• Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors.

  1987cited by this paper
• Polymorphism of dextromethorphan oxidation in a French population.

  1987cited by this paper
• Genetically determined polymorphisms in drug oxidation

  1986cited by this paper
• Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism.

  1985cited by this paper
• Polymorphic dextromethorphan metabolism: Co‐segregation of oxidative O‐demethylation with debrisoquin hydroxylation

  1985cited by this paper
• Enzymatic activation of chemicals to toxic metabolites.

  1985cited by this paper
• Purification and characterization of the rat liver microsomal cytochrome P-450 involved in the 4-hydroxylation of debrisoquine, a prototype for genetic variation in oxidative drug metabolism.

  1984cited by this paper
• Dextromethorphan as a safe probe for debrisoquine hydroxylation polymorphism.

  1984cited by this paper
• Impaired oxidation of debrisoquine in patients with perhexiline liver injury.

  1984cited by this paper
• Inherited Defects of Hepatic Drug Metabolism

  1983cited by this paper
• A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

  1980cited by this paper
• Hepatotoxicity: The adverse effects of drugs and other chemicals on the liver

  1978cited by this paper
• Polymorphic hydroxylation of Debrisoquine in man.

  1977cited by this paper

• Drug‐induced Hepatotoxicity

  2017cites this paper
• Hepatotoxicity of Psychotropic Drugs and Drugs of Abuse

  2013cites this paper
• Central role of mitochondria in drug-induced liver injury

  2012cites this paper
• Causality assessment in drug-induced hepatotoxicity

  2004cites this paper
• A review of the common properties of drugs with idiosyncratic hepatotoxicity and the "multiple determinant hypothesis" for the manifestation of idiosyncratic drug toxicity.

  2002cites this paper
• Epidemiology and Individual Susceptibility to Adverse Drug Reactions Affecting the Liver

  2002cites this paper
• Prédisposition génétique à l'hépatotoxicité des médicaments

  2002cites this paper
• Drug-induced liver diseases.

  2000cites this paper
• Georges Brohee Prize 1996. Major cytochrome P-450 families: implications in health and liver diseases.

  1997cites this paper
• Genetic predisposition to drug-induced hepatotoxicity.

  1997cites this paper
• Amineptine induced liver injury. Report of two cases and brief review of the literature.

  1996cites this paper
• Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity.

  1995cites this paper
• Possible association between poor metabolism of mephenytoin and hepatotoxicity caused by Atrium, a fixed combination preparation containing phenobarbital, febarbamate and difebarbamate.

  1994cites this paper
• Hepatic and pancreatic injury associated with amineptine therapy.

  1994cites this paper
• [Cytochromes P450 and formation of reactive metabolites. Role in hepatotoxicity of drugs].

  1993cites this paper
• [Physiopathology of drug-induced hepatopathies].

  1993cites this paper
• Intrahepatic cholestasis and phospholipidosis associated with the use of trimethoprim‐sulfamethoxazole

  1990cites this paper